Ezetimibe for the Treatment of Nonalcoholic Steatohepatitis: Assessment by Novel Magnetic Resonance Imaging and Magnetic Resonance Elastography in a Randomized Trial (MOZART Trial)

Ezetimibe inhibits intestinal cholesterol absorption and lowers low-density lipoprotein cholesterol. Uncontrolled studies have suggested that it reduces liver fat as estimated by ultrasound in nonalcoholic steatohepatitis (NASH). Therefore, we aimed to examine the efficacy of ezetimibe versus placeb...

Descripción completa

Detalles Bibliográficos
Autores principales: Loomba, Rohit, Sirlin, Claude B, Ang, Brandon, Bettencourt, Ricki, Jain, Rashmi, Salotti, Joanie, Soaft, Linda, Hooker, Jonathan, Kono, Yuko, Bhatt, Archana, Hernandez, Laura, Nguyen, Phirum, Noureddin, Mazen, Haufe, William, Hooker, Catherine, Yin, Meng, Ehman, Richard, Lin, Grace Y, Valasek, Mark A, Brenner, David A, Richards, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Steatohepatitis/Metabolic Liver Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407930/
https://www.ncbi.nlm.nih.gov/pubmed/25482832
http://dx.doi.org/10.1002/hep.27647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407930/
https://www.ncbi.nlm.nih.gov/pubmed/25482832
http://dx.doi.org/10.1002/hep.27647

Ejemplares similares